SCHEMBL6865518

SCHEMBL6865518

Nc1ccc(C(=O)Nc2cccc(C(=O)O)c2)cc1

nearest known ligand 0.72

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
HPSE Q9Y251 1/20 0.72
KMT2A Q03164 5/20 0.71
MEN1 O00255 4/20 0.71
NR1H4 Q96RI1 6/20 0.67
KCNK3 O14649 2/20 0.64
KCNK9 Q9NPC2 2/20 0.64
PKM P14618 2/20 0.61
POLB P06746 2/20 0.61
LMNA P02545 1/20 0.61
APEX1 P27695 1/20 0.61
TDP1 Q9NUW8 1/20 0.61
L3MBTL1 Q9Y468 1/20 0.60
CREBBP Q92793 1/20 0.58
TP53 P04637 1/20 0.58
SIRT1 Q96EB6 1/20 0.57
RAB9A P51151 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9249052 0.92 HPSE (0.84) HPSEKMT2AMEN1NR1H4KCNK3
SCHEMBL2126663 0.88 MEN1 (0.71) KMT2AMEN1KCNK3KCNK9PKM
SCHEMBL679144 0.88 KMT2A (0.90) HPSEKMT2AMEN1NR1H4KCNK3
SCHEMBL13381189 0.87 MEN1 (0.67) HPSEKMT2AMEN1NR1H4KCNK3
SCHEMBL28155028 0.87 KMT2A (0.61) HPSEKMT2AMEN1KCNK3KCNK9
Hydrochloric Acid SCHEMBL2106175 0.86 KMT2A (0.87) HPSEKMT2AMEN1NR1H4KCNK3
SCHEMBL6080198 0.86 KMT2A (0.59) HPSEKMT2AMEN1NR1H4KCNK3
SCHEMBL7538255 0.85 MEN1 (0.70) HPSEKMT2AMEN1PKMPOLB
SCHEMBL529184 0.85 MEN1 (0.67) HPSEKMT2AMEN1PKMPOLB
SCHEMBL29672230 0.85 PTGS1 (0.74) KMT2AMEN1KCNK3KCNK9PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12310944-B2 Selective butyrylcholinesterase inhibitor or pharmaceutically acceptable salt thereof, preparation method and use thereof CHINA PHARMACEUTICAL UNIVERSITY (CN) 2025-05-27 US disclosed
US-20230165833-A1 Selective Butyrylcholinesterase Inhibitor or Pharmaceutically Acceptable Salt Thereof, Preparation Method and Use Thereof CHINA PHARMACEUTICAL UNIVERSITY (CN) 2023-06-01 US disclosed
WO-2021042410-A1 SELECTIVE BUTYRYLCHOLINESTERASE INHIBITOR OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF 中国药科大学 2021-03-11 WO disclosed
US-6808766-B1 ALIGNMENT AGENT COMPRISING POLYURETHANE OR POLYUREA, USED IN ALIGNMENT OF LIQUID CRYSTAL MOLECULES THAT FORM LIQUID CRYSTAL ALIGNMENT FILM BY IRRADIATING THIN ALIGNMENT FILM FORMED ON SUBSTRATE WITH POLARIZED LIGHT OR ELECTRON RAYS NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2004-10-26 US disclosed
EP-1111442-A1 TREATING AGENT FOR LIQUID CRYSTAL ALIGNMENT LAYER AND LIQUID CRYSTAL DEVICE USING THE SAME, AND METHOD FOR ALIGNMENT OF LIQUID CRYSTAL Nissan Chemical Industries, Ltd. (JP) 2001-06-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230165833-A1 Selective Butyrylcholinesterase Inhibitor or Pharmaceutically Acceptable Salt Thereof, Preparation Method and Use Thereof BCHE, ACHE, BACE1 HPSE 1091/4885KMT2A 2073/4885MEN1 2484/4885
US-12310944-B2 Selective butyrylcholinesterase inhibitor or pharmaceutically acceptable salt thereof, preparation method and use thereof BCHE, ACHE, BACE1 HPSE 1291/4885KMT2A 2226/4885MEN1 2495/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.